This partnership, which officials said has the potential to be the largest ever U.S. industry-academic agreement of its kind, ...

collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Eli Lilly and Company and Purdue University are keeping their partnership alive beyond it’s previously expected years. In an ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

On May 16, Eli Lilly and Company (NYSE ... on a computer terminal with a patient in the background. The collaboration complements Lilly's existing genetic hearing loss pipeline, including AK ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned ...

Eli Lilly and Company and Purdue University announced a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next ...

On May 16, Eli Lilly and ... while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. The collaboration complements Lilly’s existing ...